公开(公告)号：US20210069295A1

公开(公告)日：2021-03-11

申请号：US16977318

申请日：2018-11-09

Applicant: STC. UNM

Inventor： Vojo P. Deretic ,  Jingyue Jia

IPC: A61K38/17 ,  A61K31/4706 ,  A61K38/05 ,  A61K31/133 ,  A61K31/16 ,  A61K31/4164 ,  A61K31/7016 ,  C07K16/28 ,  A61K31/732 ,  A61K31/4745 ,  A61K31/52 ,  A61K31/436 ,  A61K31/675 ,  A61K31/437 ,  A61K31/353 ,  A61K31/522 ,  A61K31/12 ,  A61K31/05

Abstract: The present invention is directed to the discovery that Galectins and in particular, Galectin-8 and Galectin-9 control mTor response (Galectin-8 is a mTOR inhibitor and Galectin-9 is modulator/upregulator of AMPKinase) to endomembrane damage and these compositions can be used, either alone or together, optionally in combination with a lysomotropic agent and other bioactive agents as compositions for the treatment of autophagy-elated diseases. The present invention is directed to pharmaceutical compositions and methods for treating autophagy-related diseases as described herein.